July 26th 2022
Before closing out their second module, panelists highlight remaining unmet needs in the setting of nonmetastatic castration-resistant prostate cancer.
A comprehensive discussion on factors that inform treatment selection of available AR-targeted therapy for patients with nonmetastatic CRPC.
July 19th 2022
Expert perspectives on monitoring patients with nonmetastatic castration-resistant prostate cancer and deciding when to initiate systemic therapy.
Shared insight on a clinical scenario of a patient with nonmetastatic castration-resistant prostate cancer who was treated with prostatectomy and adjuvant therapy.
July 12th 2022
Closing out their discussion on a clinical scenario of metastatic HSPC, expert panelists consider optimal patient monitoring strategies and novel imaging.
Expert panelists briefly share their excitement for trial data readouts in metastatic hormone-sensitive prostate cancer from the annual ASCO 2022 Annual meeting.
July 5th 2022
Continuing their discussion on frontline AR-targeted therapy in mHSPC, experts define how accessibility and patient eligibility impact treatment selection.
Expert perspectives on frontline AR-targeted therapy in metastatic hormone-sensitive prostate cancer, with deference to recent clinical trial data on triplet therapy.
June 28th 2022
A brief review of the respective roles of multidisciplinary care and genetic testing in patients diagnosed with metastatic hormone-sensitive prostate cancer.
Centering discussion on a clinical scenario of metastatic hormone-sensitive prostate cancer, expert panelists consider how they might approach frontline therapy in this setting.
May 25th 2022
Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.
Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
May 18th 2022
A broader perspective on the management of bone and visceral metastases in metastatic CRPC given the current treatment landscape.
Shifting their focus to 177Lu-PSMA-617 in metastatic CRPC, expert panelists consider its role in sequencing therapy and managing bone metastases.
May 11th 2022
A brief discussion on how to select and apply novel imaging strategies in patients with metastatic castration-resistant prostate cancer.
Shared insight on the role of imaging as a phenotypic biomarker in patients being treated for metastatic castration-resistant prostate cancer.
May 4th 2022
Expert perspectives on how DNA alterations may inform the selection and use of PARP inhibitors in metastatic CRPC.
A broad overview of the armamentarium for metastatic CRPC followed by detailed discussion on the role of PARP inhibitors in this setting.
April 27th 2022
Comprehensive insight on results from the ARASENS trial and how panelists will be incorporating what was learned into real-world clinical practice.
Focusing on treatment selection factors in metastatic HSPC, panelists consider how the ARASENS trial redefined treatment approaches.